Bluejay Diagnostics Q1 FY26 net loss unchanged at $1.9 million

• Bluejay Diagnostics posted a net loss of about $1.9 million in Q1 2026, roughly flat versus Q1 2025.
• Cash and cash equivalents totaled about $3.7 million as of March 31, 2026.
• SYMON-II pivotal study enrollment reached about 680 patients as of May 5 toward a 750-patient target.
• Cartridge manufacturing readiness work with Sanyoseiko resolved technical process issues; company continued pursuing an FDA-focused path toward a future Symphony IL-6 510(k) submission after analytical and clinical validation.
• CEO Neil Dey cited “meaningful operational progress,” pointing to study enrollment momentum and manufacturing readiness aimed at moving Symphony toward regulatory readiness and future commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071601PRIMZONEFULLFEED9715149) on May 07, 2026, and is solely responsible for the information contained therein.